ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional Results available

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

ClinicalTrials.gov ID: NCT02511106

Public ClinicalTrials.gov record NCT02511106. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Double-blind, Randomized, Placebo-controlled Multi-centre, Study to Assess the Efficacy and Safety of AZD9291 Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA).

Study identification

NCT ID
NCT02511106
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
682 participants

Conditions and interventions

Interventions

  • AZD9291 80 mg/40 mg Drug
  • Open-label AZD9291 80 mg/40 mg Drug
  • Placebo AZD9291 80 mg/40 mg Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 130 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 20, 2015
Primary completion
Apr 10, 2022
Completion
Jan 30, 2029
Last update posted
Mar 29, 2026

2015 – 2029

United States locations

U.S. sites
23
U.S. states
14
U.S. cities
23
Facility City State ZIP Site status
Research Site Los Angeles California 90048
Research Site Santa Monica California 90404
Research Site Santa Rosa California 95403
Research Site Torrance California 90505
Research Site Grand Junction Colorado 81501
Research Site New Haven Connecticut 06520
Research Site Norwalk Connecticut 06856
Research Site Fort Myers Florida 33901
Research Site Pembroke Pines Florida 33028
Research Site St. Petersburg Florida 33705
Research Site Athens Georgia 30607
Research Site Honolulu Hawaii 96819
Research Site Chicago Illinois 60612
Research Site Elk Grove Village Illinois 60007
Research Site Bethesda Maryland 20817
Research Site Brick New Jersey 08724
Research Site Florham Park New Jersey 07932
Research Site Mineola New York 11501
Research Site Pawtucket Rhode Island 02860
Research Site Chattanooga Tennessee 37404
Research Site Nashville Tennessee 37203
Research Site San Antonio Texas 78229
Research Site Fort Belvoir Virginia 22060

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 215 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02511106, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 29, 2026 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02511106 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →